Table SIII. Characteristics of patients treated with tumour necrosis factor (TNF)-α and interleukin (IL)-12/23 antagonists

	TNF-α	IL-12/23
Number of treatments	173	23
Age, years, mean±SD	47.0±12	48.9±12
Sex, female, %	36	35
Psoriasis arthritis, present, %	46	35
Previous systemic treatments, mean±SD	2.7±1	4.8±2
Median [IQR]	2.0 [2, 3]	4.0 [3, 6]
Concomitant methotrexate, %	15	0
Biologic, %		
Adalimumab	65	0
Etanercept	35	0
Ustekinumab	0	100
Baseline PASI, mean±SD (*n*)	10.3±7 (161)	10.6±6 (22)
Median [IQR]	9.1 [5, 14]	11.1 [7, 15]
Baseline NLR, gmean[SD] (*n*)	2.9 [2, 5] (148)	3.1 [2, 6] (21)
Median [IQR]	2.7 [2, 4]	3.0 [3, 5]
Treatment duration, months, mean±SD	21±19	19±11

PASI: Psoriasis Area and Severity Index; NLR: neutrophil-to-lymphocyte ratio; SD: standard deviation; gmean: geometric mean.